(NYSE: ANVS) Annovis Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.71%.
Annovis Bio's earnings in 2026 is -$24,884,444.On average, 6 Wall Street analysts forecast ANVS's earnings for 2026 to be -$37,777,218, with the lowest ANVS earnings forecast at -$39,218,975, and the highest ANVS earnings forecast at -$31,723,958. On average, 4 Wall Street analysts forecast ANVS's earnings for 2027 to be -$33,791,183, with the lowest ANVS earnings forecast at -$35,842,507, and the highest ANVS earnings forecast at -$31,167,397.
In 2028, ANVS is forecast to generate -$55,958,200 in earnings, with the lowest earnings forecast at -$53,763,761 and the highest earnings forecast at -$57,604,029.